


## Introduction to mAb Peptide Mapping

### LC-MS/MS Conditions

Immune system IgG-like protein that recognizes specific targets (antigens). Contains ~ 1320 amino acids in 4 polypeptide chains:

- Two identical heavy chains (long chains)
- Two identical light chains (short chains)




### Critical Quality Attributes

**Critical Quality Attribute:** "physical, chemical, biological or microbiological property or characteristics that should be within an appropriate limit, range, or distribution to ensure the desired product quality." ICH guidance Q8(R2)

Attribute Category	What can be measured?
Product- specific variants	<ul style="list-style-type: none"> <li>MW</li> <li>Sequence variants</li> <li>Charge distribution</li> <li>PTMs (oxidation, deamidation/isomerization, N/C-terminal processing, glycosylations)</li> <li>Aggregation (higher order structure variants)</li> </ul>
Process-related impurities	<ul style="list-style-type: none"> <li>Host cell proteins</li> <li>DNA</li> <li>Raw materials (cell culture media, buffers, protein A)</li> <li>Leachables from product contact materials</li> </ul>
Obligatory (drug product attributes)	<ul style="list-style-type: none"> <li>pH</li> <li>Excipients</li> <li>Concentration</li> <li>Osmolality</li> <li>Adventitious agents (viruses, mycoplasma, endotoxins).</li> <li>Appearance</li> </ul>

### Risk Assessment of pCOAs (example)



Biologicals 44 (2016) 291e305.

<http://dx.doi.org/10.1016/j.biologics.2016.06.005>

## Sample Prep Steps

### Protein Digestion Steps

- Denaturation** - Proteins can be denatured using high temperatures or by addition of chaotropic agents such as urea, guanidinium hydrochloride, and acetonitrile.
- Reduction of disulfide bonds** - Dithiothreitol (DTT) reduces the disulfide bonds between cysteine residues, allowing the protein to become fully unfolded.
- Alkylation** - An alkylating agent such as iodoacetic acid (IAA) is added to alkylate all of the cysteine residues, preventing the formation of disulfide bonds.
- Dilution** - Salts and other reagents that may denature the enzyme must be removed or diluted to ensure successful digestion.
- Digestion** - Enzyme is added to the protein solution.

### Denaturants

Denaturation	Limitations
8 M Urea	<ul style="list-style-type: none"> <li>Heat breaks urea down to cyanate which can carbamate lysine and arginine residues</li> <li>Needs dilution to &lt;2M urea for trypsin activity</li> </ul>
6M GnHCl	<ul style="list-style-type: none"> <li>Lower trypsin digestion efficiency, even at 0.9 M concentration.</li> <li>Needs extensive dilution or buffer exchange</li> </ul>
SDS	<ul style="list-style-type: none"> <li>Not MS compatible (ion suppressing)</li> <li>Must be removed prior to MS</li> </ul>
MS-friendly surfactants	<ul style="list-style-type: none"> <li>Acid-labile surfactants (PPS Silent® Surfactant, Rapigest™, ProteaseMax)</li> <li>Surfactants yielding insoluble precipitates under low pH (e.g., DDC)</li> <li>Invitrosol™ does not interfere with your chromatography separations and does not contaminate LC/MS instrumentation</li> </ul>


### Removal of Denaturant

Cleanup type	Strengths	Weaknesses
Dialysis	<ul style="list-style-type: none"> <li>Minimal sample loss</li> </ul>	<ul style="list-style-type: none"> <li>Long clean up times</li> </ul>
Desalting column	<ul style="list-style-type: none"> <li>Rapid desalting/Cleanup</li> </ul>	<ul style="list-style-type: none"> <li>Final sample concentration lower</li> </ul>
Molecular weight cut-off filters (MWCO) FASP	<ul style="list-style-type: none"> <li>Integrated protein digestion, denaturant and detergent removal.</li> </ul>	<ul style="list-style-type: none"> <li>Susceptible to sample loss</li> <li>Final sample concentration higher</li> </ul>
In-Stage Tip	<ul style="list-style-type: none"> <li>Can be easily automated</li> </ul>	
SP3		

SP3 - Single-Pot Solid-Phase-enhanced Sample Preparation  
FASP - Filter-aided sample preparation

### Reducing reagents

- Dithiothreitol (DTT)**
- Needs pH values above 7
  - Can promote Met oxidation (metal-catalyzed reaction)




Beta-mercaptoethanol (BME)

### Alkylating reagents

- Iodoacetic acid (IAA):**
- Slower reacting
  - Carboxymethyl (+58 Da) is added to reduced cysteines

### Iodoacetamide (IAM):

- Most common (fastest reacting).
- Carbamidomethyl (+57 Da) added to reduced cysteines
- Quenching with DTT can help with non-specific alkylation of other amino acids





### Chloroacetamide:

- Less reactive and more stable in solution than iodoacetamide
- Less non-specific alkylation of other amino acids and side reactions
- Light sensitive reagents

### Trypsin

- Serine protease considered the gold standard for protein digestion.
- Well-defined specificity for C-terminal K and R.
- Potential missed cleavages when K and R are followed at N-term by D/Q and C-term by P.



Column: Biozen 2.6µm XB-C18

Dimensions: 150 x 2.1 mm

Part No.: 00F-4768-AN

Mobile Phase: A: 0.1 % Formic Acid in H2O

B: 0.1 % Formic Acid in ACN

Gradient: 1-50% B in 50 minutes

Flow Rate: 0.3 mL/min

Temperature: 40 °C

Detection: Q-TOF

Sample: Trastuzumab

## Selectivity Drivers

### Mobile Phase and Acidic Modifiers

Commonly used mobile phase contains:

- Water
- Acetonitrile, MeOH, IPA
- Acidic modifier: Formic acid (FA), Trifluoroacetic acid (TFA), Acetic acid

IPA: Better recovery of hydrophobic peptides

Formic acid (FA)

Trifluoroacetic acid (TFA)


Acetic acid

Better peptide unfolding

Less free-silanol groups

Better retention with TFA (IP)

### Effect of TFA and Formic Acid



Column: Biozen 1.6µm PS-C18

Dimensions: 150 x 2.1 mm

Mobile Phase: A: 0.1 % Acidic Modifier in H2O

B: 0.1 % Acidic Modifier in ACN

Gradient: 1-50% B in 50 minutes

Flow Rate: 0.3 mL/min

Temperature: 40 °C

Detection: UV @ 214 nm

Sample: Tryptic Digest, NIST mAb

### Comprehensive Evaluation of Reversed-Phase Columns for Peptide Mapping

Gain insights from a detailed comparison of 13 reversed-phase columns tested with complex peptide mixtures.


The study assesses performance across acidic, basic, and long-chain peptides, revealing how column chemistry and hardware influence mapping quality. Findings support data-driven column selection for improved resolution, efficiency, and reproducibility in biopharma applications.

- Review the study to strengthen your peptide mapping strategy.

### Type of Gradients


#### Shallow gradients:

- Slope 0.5 – 1 %B/min
- Provide the best separation.
- Could cause a switch in peak order.



#### Step gradients:

- Quickly skip time windows where peptides don't elute and increase overall peak capacity.
- Focus on specific peptides



### Temperature

- ✓ Increase in efficiency with temperature. More significant for fully porous particles e.g. bioZen peptide PS-C18

- ✓ Higher temperatures improve peak shape of peptides from proline-rich proteins (cis-trans isomerization rate)

- ✗ On-column thermal peptide cleavage in presence of 0.1 % formic acid (Asp-X and X-Asp)

- ✗ On-column thermal promotion of artificial modifications: oxidation of Met, Pyro-Glu (N-term Q/E) deamidation of Asn to Asp, and isomerization of Asp.

Column: Biozen 1.6µm Peptide PS-C18

Dimensions: 150 x 2.1 mm

Mobile Phase: A: 0.1 % Formic Acid in Water

B: 0.1 % Formic Acid in Acetonitrile


Gradient: 1-50% B in 50 minutes

Flow Rate: 0.3 mL/min

Temperature: 40 °C

Detection: Q-TOF

Sample: Trastuzumab Digest, 1 µg



Temp (°C)	Peak Capacity
60	457
50	513
40	343

### Effect of Column Dimensions

#### What can we modify?


- Column Length
- Column ID

Column Length effect:


Efficiency is proportional to column length.

- Longer columns provide higher resolution, but longer run times
- Very complex samples could warrant the use of a longer column (250 mm)
- In general, ID of 2.1 mm are the common choice for LC-MS/MS
- For tryptic peptides pore sizes of ~100 Å is ideal. Larger pore sizes can be considered for larger peptides (middle-out/down approach).


### Overlap of TIC Traces for Analytical Flow (Red) and Micro Flow (Purple) of AAV9 Viral Proteins Tryptic Digest.



### Increase in Ion Intensity by Using Micro Flow.




## Selection of Stationary Phases




	Biozen Peptide XB-C18	Biozen Peptide PS-C18	Biozen Peptide Polar
Recommended Use	Overall retention of both acidic and basic peptides for both peptide mapping and peptide quantitation applications	Excellent retention of peptides for both peptide mapping and peptide quantitation applications	Enhanced selectivity and retention for polar peptides without diminishing non-polar retention mechanism.
Particle Size (µm)	1.7, 2.6, 5	1.6, 3	1.6, 3
Pore Size (Å)	100	100	100
Surface Area (m²/g)	200	260	260
Carbon Load	10	9	9
pH Stability	1.5-9	1.5-8.5	1.5-8.5

### Core-Shell Technology



Using sol-gel nano-structuring, a durable and uniform porous shell is formed over a solid silica core. Combined with advanced packing technology, this process delivers highly reproducible columns with excellent efficiency and sensitivity

### Thermally Modified Fully Porous



Through a proprietary series of thermal processing steps, we eliminate micropores and further improve consistency, leading to higher column efficiency and reproducibility.

## Biozen provides improved sequence coverage and sensitivity compared to equivalent alternatives

Biozen 1.6µm Peptide PS-C18, 137 Unique Peptides

Waters® ACQUITY® 1.7µm Peptide CSH, 103 Unique Peptides

### Method Conditions:

Column: Biozen 1.6µm Peptide PS-C18

Waters ACQUITY 1.7µm Peptide CSH

Dimensions: 150 x 2.1 mm

Part No.: 00F-4770-AN (PS-C18)

Mobile Phase: A: 0.1 % Formic Acid in Water


B: 0.1 % Formic Acid in Acetonitrile

Gradient: 1-50% B in 50 minutes

Flow Rate: 0.3 mL/min

Detection: SCIEX X500B Q-TOF

Sample: Trastuzumab Digest, 1 µg



Comparative separations may not be representative of all applications.

## Comprehensive Evaluation of Reversed-Phase Columns for Peptide Mapping

- Compare 13 reversed-phase columns with complex peptide mixtures.
- See performance across acidic, basic, and long-chain peptides.
- Discover how column chemistry and hardware shape mapping quality.
- Choose columns confidently for better resolution, efficiency, and reproducibility in biopharma

Review the study to strengthen your peptide mapping strategy.

GET THE INSIGHTS



Biozen is a trademark of Phenomenex. ACQUITY is a trademark of Waters Corporation. Comparative separations may not be representative of all applications. Phenomenex is in no way affiliated with Waters Corporation. FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2024 Phenomenex, Inc. All rights reserved.

Have questions or want more details? We would love to help!  
Visit [www.phenomenex.com/Chat](http://www.phenomenex.com/Chat) to get in touch with one of our Technical Specialists